Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency

  • Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira®* and Remicade®†
  • Comprehensive data packages demonstrate each biosimilar matches its respective reference medicine in terms of quality, efficacy and safety
  • These regulatory submissions follow soon after two positive CHMP opinions** for Sandoz biosimilars etanercept and rituximab further reinforcing Sandoz immunology pipeline and the broader Novartis immunology portfolio

    • …

/by

At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018

  • Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020
  • Focused and taking steps to become stronger and more integrated through centralized manufacturing, development and business services
  • Poised for next growth phase, anticipated to begin in 2018

Boston, May 31, 2017 – Today Novartis holds its fourth annual Meet Novartis Management event at its research headquarters in Cambridge, MA, giving …

/by

At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018

  • Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020
  • Focused and taking steps to become stronger and more integrated through centralized manufacturing, development and business services
  • Poised for next growth phase, anticipated to begin in 2018

Boston, May 31, 2017 – Today Novartis holds its fourth annual Meet Novartis Management event at its research headquarters in Cambridge, MA, giving …

/by